Back to top
more

ADMA Biologics (ADMA)

(Delayed Data from NSDQ)

$13.08 USD

13.08
2,824,611

-0.50 (-3.68%)

Updated Jul 25, 2024 04:00 PM ET

After-Market: $13.10 +0.02 (0.15%) 6:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Immunovant (IMVT) Up 3% as Q3 Earnings Top, Pipeline in Focus

by Zacks Equity Research

Immunovant (IMVT) gains 3% on encouraging fiscal third-quarter 2024 results. Pipeline development is on track, with several data readouts scheduled from both batoclimab and IMVT-1402 programs.

New Strong Buy Stocks for February 13th

by Zacks Equity Research

IKT, ETRN, ADMA, AFRM and ORC have been added to the Zacks Rank #1 (Strong Buy) List on February 13, 2023.

Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.

Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Zoetis' (ZTS) higher companion animal product sales are expected to have driven revenues in the fourth quarter of 2023, partially offset by declining livestock product sales.

Abhinab Dasgupta headshot

3 Medical Stocks to Buy as the Sector Continues to Grow

by Abhinab Dasgupta

HCA Healthcare (HCA), ADMA Biologics (ADMA) and Exelixis (EXEL) are three medical stocks that you can look into as the sector continues to sustain its end-of-the-year momentum.

Adma Biologics (ADMA) Stock Declines While Market Improves: Some Information for Investors

by Zacks Equity Research

Adma Biologics (ADMA) closed at $5.18 in the latest trading session, marking a -1.71% move from the prior day.

Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic?

by Zacks Equity Research

The average brokerage recommendation (ABR) for Adma Biologics (ADMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Does Adma Biologics (ADMA) Have the Potential to Rally 31.55% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 31.6% in Adma Biologics (ADMA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Adma Biologics (ADMA) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Adma Biologics (ADMA) closed the most recent trading day at $5.23, moving -1.32% from the previous trading session.

Bristol Myers' (BMY) sBLAs for Breyanzi Get FDA Priority Tag

by Zacks Equity Research

Bristol Myers' (BMY) two sBLAs for Breyanzi in relapsed/refractory follicular lymphoma and relapsed/refractory mantle cell lymphoma receive FDA acceptance and priority review.

Best Momentum Stocks to Buy for January 31st

by Zacks Equity Research

ADMA, EKSO and IKT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 31, 2024.

Novo Nordisk (NVO) Q4 Earnings Top, GLP-1 Drugs Boost Sales

by Zacks Equity Research

Novo Nordisk (NVO) reports better-than-expected fourth-quarter results, beating both earnings and revenues, driven by strong sales of Diabetes and Obesity care products.

New Strong Buy Stocks for January 31st

by Zacks Equity Research

ADMA, IKT, YPF, AVXL and EKSO have been added to the Zacks Rank #1 (Strong Buy) List on January 31, 2024.

Adma Biologics (ADMA) is on the Move, Here's Why the Trend Could be Sustainable

by Zacks Equity Research

Adma Biologics (ADMA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Has Adicet Bio (ACET) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.

Best Momentum Stocks to Buy for January 24th

by Zacks Equity Research

ADMA, CM and HEAR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 24, 2023.

Unicycive (UNCY) Up on Positive Hyperphosphatemia Study Update

by Zacks Equity Research

Unicycive (UNCY) rises after the encouraging progress in the late-stage development of its lead candidate, OLC, for the hyperphosphatemia indication. The NDA submission is expected around mid-2024.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Outlook (OTLK) Surges 31% on Regulatory Update for AMD Study

by Zacks Equity Research

Outlook (OTLK) stock rises after aligning with the FDA regarding the protocols of a non-inferiority study of ONS-5010 for AMD. The study is set to become the basis for BLA resubmission by 2024-end.

New Strong Buy Stocks for January 24th

by Zacks Equity Research

ADMA, PBPB, YPF, CM and AVXL have been added to the Zacks Rank #1 (Strong Buy) List on January 24, 2023.

Pharvaris (PHVS) Up as FDA Lifts Clinical Hold on HAE Program

by Zacks Equity Research

Pharvaris (PHVS) rises 6% after the FDA lifts the clinical hold on the investigational candidate, deucrictibant, for the prophylactic treatment of HAE attacks.

Here's Why You Should Add Xenon (XENE) to Your Portfolio Now

by Zacks Equity Research

Xenon's (XENE) late-stage studies in epilepsy are progressing well. The company is also gearing up to initiate a late-stage study for the MDD indication in 2024.

Verastem (VSTM) Up 8% on Fast Track Tag for NSCLC Combo Therapy

by Zacks Equity Research

Verastem's (VSTM) avutometinib/Lumakras combination therapy gets the FDA's Fast Track designation to treat KRAS G12C-mutant metastatic NSCLC patients. The stock gains 8% in response.

Exelixis (EXEL) Reports Positive EU Patent Ruling for Cabometyx

by Zacks Equity Research

Exelixis (EXEL) gets a favorable ruling from the European Patent Office in a lawsuit related to its oral oncology drug, Cabometyx.

Wall Street Analysts Predict a 27.09% Upside in Adma Biologics (ADMA): Here's What You Should Know

by Zacks Equity Research

The consensus price target hints at a 27.1% upside potential for Adma Biologics (ADMA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.